Kevin Slawin Explained

Kevin M. Slawin
Birth Date:1961
Birth Place:Brooklyn, New York, United States
Education:BA Columbia University
MD Columbia University College of Physicians & Surgeons
Occupation:Prostate cancer physician and biotechnology entrepreneur
Known For:Co-discoverer of P2PSA, a key component of the Prostate Health Index test (phi test) and founder of Bellicum Pharmaceuticals, Inc.

Kevin M. Slawin (born 1961) is an American physician and the founder of Bellicum Pharmaceuticals and the Vanguard Urologic Institute at Memorial Hermann Medical Group. He was also the Director of Urology at Memorial Hermann Hospital. Slawin specializes in the diagnosis and treatment of urologic cancers and robotic surgery. He is also possesses patents related to the advancement of prostate cancer diagnosis, staging and treatment[1] and to the cellular immunotherapy of cancer.

Education

Slawin graduated with a Bachelor of Arts degree in Biochemistry from Columbia University,[2] and gained his medical degree in 1986 from Columbia College of Physicians and Surgeons.[3] Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer.[4]

Academic Medical career

Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994,[5] and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, after the well known Houston philanthropist. In 2007, he left the full-time faculty of Baylor to found The Vanguard Urologic Institute, that works on advancing treatment of urologic diseases. Slawin is a pioneer in the development of Robotic-Assisted Laparoscopic Prostatectomy.[6]

Innovation

Robotic-Assisted Laparoscopic Prostatectomy

Discoveries

Bellicum Pharmaceuticals, Inc.

Slawin founded Bellicum Pharmaceuticals, Inc.[17] in 2004. He served as Executive Chairman and Chief Medical Officer until 2014. On December 18, 2014, Bellicum completed a successful IPO on the NASDAQ (NASDAQ: BLCM). In 2015, Dr. Slawin transitioned to the roles of Chief Technology Officer, member of the Board of Directors, and a significant shareholder.[18] [19] In 2016, Slawin transitioned out of an operational role at the company. In 2017, Slawin resigned from the Board of Directors.

Notes and References

  1. Web site: 25 June 2014 . New prostate cancer test gives more specific, reliable results . 27 January 2015 . Chron.cosm.
  2. Web site: Columbia College Today . dead . https://web.archive.org/web/20160305090728/http://www.college.columbia.edu/cct_archive/sep_oct07/updates4.php . 2016-03-05 . 2015-06-25 . Columbia.edu.
  3. Web site: America's Top Doctors - The Best in American Medicine . 2015-06-25 . Castleconnolly.com.
  4. Web site: Prostate cancer a worry for T&T. Guardian.co.tt. 27 January 2015.
  5. Web site: Kevin Slawin: Taking bench to bedside - from the Labs - Baylor College of Medicine - Houston, Texas . September 11, 2015 . dead . https://web.archive.org/web/20150626120207/https://www.bcm.edu/archives/fromthelab/vol05/is7/0906-4.html . June 26, 2015 .
  6. Web site: Memorial Hermann-Texas Medical Center Urologist Among Elite Group of Prostatectomy Experts in the Nation . 2015-06-25 . Memorialhermann.org.
  7. Low Annual Caseloads in US Surgeons Conducting Radical Prostatectomy. The Journal of Urology. 182. 6. 2677–2679. 2860275. 2009. Savage. C. J.. Vickers. A. J.. 10.1016/j.juro.2009.08.034. 19836787.
  8. Mikolajczyk. Stephen. Millar. L. S.. Wang. T. J.. Rittenhouse. H. G.. Marks. L. S.. Song. W. Wheeler. T. M.. Slawin. K. M.. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Research. 60. 3. 756–759. 10676664. 2000.
  9. Web site: Patent US6423503 - Forms of free prostate-specific antigen (PSA) and their association with ... - Google Patents. Google.com. 2015-06-25.
  10. Web site: K8 Science: Kevin Slawin: Taking bench to bedside . 26 July 2011 . bot: unknown . https://web.archive.org/web/20110726213311/http://www.k8science.org/from-the-labs/article.cfm?art=401 . 26 July 2011 .
  11. Web site: ProPSA Test for Detection of Prostate Cancer Validated - National Cancer Institute . September 11, 2015 . dead . https://web.archive.org/web/20110303030620/http://www.cancer.gov/newscenter/pressreleases/proPSA . March 3, 2011 .
  12. Web site: NCI Cancer Bulletin for July 10, 2012 - National Cancer Institute . dead . https://web.archive.org/web/20141006123848/http://www.cancer.gov/ncicancerbulletin/071012/page8 . October 6, 2014 . September 11, 2015.
  13. Web site: New Prostate Cancer Blood Test Now Available in the US : Press release . dead . https://web.archive.org/web/20150623205811/https://prostatehealthindex.us/wp-content/uploads/sites/2/2014/04/BEC2014_phi_NationalAvailability_PressRelease_FINAL3.pdf . 2015-06-23 . 2015-06-25 . Prostatehealthindex.us.
  14. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo . 11. 2 . 10.1038/nm1183. 15665830 . 130–137. Nature Medicine. 2005 . Hanks . Brent A. . Jiang . Jianghong . Singh . Rana A K. . Song . Weitao . Barry . Michael . Huls . Mary H. . Slawin . Kevin M. . Spencer . David M. . 33397197.
  15. Web site: Patent US7404950 - Induced activation in dendritic cell. Google.com. 2015-06-25.
  16. Web site: 2014-12-18 . Houston's Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO . 7 June 2015 . Xconomy.com.
  17. Web site: Bellicum Pharmaceuticals IPO . 7 June 2015 . NASDAQ.
  18. Web site: Bellicum Pharmaceuticals: Has The Bell Finally Tolled For Cancer? . 7 June 2015 . Seeking Alpha.
  19. Web site: Bellicum Pharmaceuticals Major Shareholders. Yahoo Finance. 7 June 2015.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Kevin Slawin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.